Ignite Creation Date:
2024-05-06 @ 8:24 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06368063
Status:
RECRUITING
Last Update Posted:
2024-05-08
First Post:
2024-04-11
Brief Title:
The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer
Sponsor:
Health Science Center of Xian Jiaotong University
Organization:
Health Science Center of Xian Jiaotong University
Study Overview
Official Title:
Study on the Efficacy and Safety of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is a multicenter prospective clinical study aimed at evaluating the efficacy and safety of Huaier Granule in postoperative adjuvant treatment of resectable pancreatic cancer
Detailed Description:
The study is a multicenter prospective clinical study expected to include subjects who visited the selected research center from April 2024 to March 2026 underwent radical tumor resection surgery and were pathologically diagnosed with pancreatic adenocarcinoma The subjects are divided into two groups One group is the standard chemotherapy group with a planned inclusion of no less than 428 subjects The chemotherapy will be treated using the Class 1A chemotherapy regimen recommended by the 2022 version of the CSCO guidelines One group is the Huaier treatment group with a planned inclusion of no less than 214 subjects All subjects voluntarily give up the postoperative adjuvant treatment recommended by the guidelines and only choose Huaier granules for postoperative adjuvant treatment A total of no less than 642 subjects are planned to be included
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None